Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor

American Journal of Veterinary Research

Volumn 72, Issue 12, 2011, Pages 1631-1638

  Grosenbaugh, Deborah A ^a   Leard, A Timothy ^a   Bergman, Philip J ^b   Klein, Mary K ^c   Meleo, Karri ^d   Susaneck, Steven ^e   Hess, Paul R ^f   Jankowski, Monika K ^g   Jones, Pamela D ^g   Leibman, Nicole F ^b   Johnson, Maribeth H ^h   Kurzman, Ilene D ⁱ   Wolchok, Jedd D ^j  

^a ANIMAL MEDICAL CENTER   (United States)

^b Southwest Veterinary Oncology   (United States)

^c Animal Cancer Specialists   (United States)

^d Greater Houston Veterinary Specialists   (United States)

^e NORTH CAROLINA STATE UNIVERSITY   (United States)

^f Southwest Veterinary Oncology   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j BrightHeart Veterinary Centers   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUTYR VACCINE; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL LAMENESS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOMA; MALE; MELANOMA; MORTALITY; MOUTH CANCER; MULTICENTER STUDY; NONHUMAN; ORAL MALIGNANT MELANOMA; OUTCOME ASSESSMENT; PAIN; PROSPECTIVE STUDY; SKIN BRUISING; SWELLING; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 82755181916     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.72.12.1631     Document Type: Article

References (23)

1. MacEwen EG, Patnaik AK, Harvey HJ, et al. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 1986;4:397-402.
2. Lascelles BDX, Thomson MJ, Dernell WS, et al. Combined dorsolateral and intraoral approach for the resection of tumors of the maxilla in the dog. J Am Anim Hosp Assoc 2003;39:294-305.
3. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
4. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004;224:388-394.
5. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 2003;44:352-359.
6. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999;5:4249-4258.
7. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 1979;16:32-40.
8. Harvey HJ, MacEwen EG, Braun D, et al. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 1981;178:580-582.
9. Bergman PJ, Wolchok JD. Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Ther 2008;6:817-826.
10. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006;6:8-17.
11. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9:1284-1290.
12. Wang S, Bartido S, Yang G, et al. A role for a melanosome transport signal in accessing the MHC Class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol 1999;163:5820-5826.
13. Goubier A, Fuhrmann L, Forest L, et al. Superiority of needlefree transdermal plasmid delivery for the induction of antigenspecific IFNγ T cell responses in the dog. Vaccine 2008;26:2186-2190.
14. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-1264.
15. Bowne WB, Srinivasan R, Wolchok JD, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-1722.
16. Bergman PJ, Camps-Palau MA, McKnight JA. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24:4582-4585.
17. Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 2010;28:1936-1941.
18. US FDA. Guidance for industry-E10 choice of control group and related issues in clinical trials. May 2001. Available at: www.fda.gov./RegulatoryInformation/Guidances/ucm 125802. htm#P590_82931. Accessed Aug 2, 2011.
19. Taylor JMG, Braun TM, Li Z. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm phase II design. Clin Trials 2006;3:335-348.
20. Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007;15:2044-2050.
21. Yuan J, Gioffrey YK, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp 100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun 2009;9:5-12.
22. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009;15:3856-3865.
23. Bergman PJ. Cancer immunotherapy. Top Companion Anim Med 2009;24:130-136.